Posted by Michael Wonder on 10 Oct 2023
US FDA approves FoundationOne CDx as a companion diagnostic for Lilly’s Retevmo (selpercatinib) for certain patients with solid tumours
9 October 2023 - Foundation Medicine’s tissue based comprehensive genomic profiling test is now FDA approved to identify patients with solid tumours with RET gene fusions who may benefit from treatment with Retevmo.
Foundation Medicine today announced that it has received approval from the US FDA for FoundationOne CDx to be used as a companion diagnostic for Eli Lilly and Company’s Retevmo (selpercatinib), which was approved by the FDA for the treatment of adult patients with locally advanced or metastatic solid tumours with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.
